Advertisement
Singapore markets close in 15 minutes

  • Straits Times Index

    3,288.00
    -5.13 (-0.16%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE 100

    8,092.68
    +52.30 (+0.65%)
     

  • Bitcoin USD

    63,829.11
    -2,712.55 (-4.08%)
     

  • CMC Crypto 200

    1,362.04
    -20.53 (-1.48%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,338.90
    +0.50 (+0.02%)
     

  • Crude Oil

    83.19
    +0.38 (+0.46%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.30
    -1.18 (-0.08%)
     

  • Jakarta Composite Index

    7,151.96
    -22.57 (-0.31%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

ArQule (ARQL) Shows Strength: Stock Adds 6 % in Session

Zacks Equity Research

ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company since Nov 7, as the stock is now up nearly 17%.

In the last 30-day frame, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

ArQule currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Other well-performing stocks in the med-drugs industry include Lannett Company, Inc. (LCI), Biodel Inc. (BIOD) and Durata Therapeutics, Inc. (DRTX). All three sport a Zacks Rank #1.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


ARQULE INC (ARQL): Free Stock Analysis Report

LANNETT COMP (LCI): Free Stock Analysis Report

DURATA THERAPEUTICS INC (DRTX): Free Stock Analysis Report

BIODEL INC (BIOD): Free Stock Analysis Report


Zacks Investment Research